Study treatments and design
Data used in this study were derived from an adaptive, seamless, randomized, double-blind, placebo-controlled Phase I/II/III clinical trial that evaluated the efficacy, safety, and tolerability of CAS + IMD in outpatients with COVID-19. The trial enrolled patients with varying baseline characteristics over time and varied the doses administered in an adaptive fashionBriefly, patients in the Phase I/II portion of the trial (The total duration of the symptom assessment period was 28 days (days 1–29), although here we present data up to day 15. Throughout the study, patients used an electronic diary to provide daily self-reported information about COVID-19 symptoms